🇺🇸

US SEC Filing Intelligence

· daily

Global High-Priority Regulatory Events — March 27, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include M&A activity (e.g., mergers, spin-offs, amalgamations), regulatory non-compliances and penalties (prevalent in Indian firms), distress signals like debt defaults, delisting risks, and going concern doubts in biotechs, alongside positive credit facilities and IPOs/SPACs. Period-over-period trends show mixed revenue performance: standout growth in Alamar Biosciences (+195% YoY to $74.2M), Sportradar (+17% to €1,290M), Equifax (+7% to $6.075B), and Indivior (+4% to $1.24B), but sharp declines in Origin Materials (-40% FY2025 to $18.9M) and Sarda Proteins (revenue to 57,627 Lakhs from 97,596 Lakhs). Biotech sector exhibits bifurcation with AnaptysBio spin-off ($180M cash runway) contrasting VivoSim and BiomX distress; financials see refinancing positives (Enterprise $1.5B facility, Delek new credit agreement). Critical implications: heightened insolvency risks in infrastructure/Indian firms (IL&FS default, Shirpur/Setubandhan CIRP), M&A catalysts for value unlock (Two Harbors $10.80/share takeover, Bank of Nagoya integration), and proxy-driven governance shifts (Norwegian Cruise board refresh). Portfolio-level patterns flag Indian regulatory fines averaging ~₹5-12L across 5+ firms, biotech cash runways extending to 2027 with dilution risks, and energy/REITs prioritizing capital returns amid stable metrics.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — March 27, 2026

Across 50 10-K filings for FY ended Dec 31, 2025, a stark divide emerges: 30+ ABS trusts (Ally Auto, Exeter Auto, Navient/SLM Student Loan) confirm full servicing compliance with neutral sentiment and no material issues or metrics, signaling stability in securitized auto/student loan markets. Operating companies (20 filings) reveal volatile growth, with digital asset firms (BitGo +424% YoY revenue to $16.2B, FG Nexus +210% to $2.4M, American Bitcoin +159% to $185M) driving top-line surges but massive net losses from unrealized digital asset impairments (e.g., BitGo -$14.8M vs +$156K prior). SPACs/blank checks (OTG, Republic Digital, Galata II, Launch Two) hold steady trusts yielding interest income (e.g., Launch Two net income +302% YoY to $8.9M), while biotech/tech (Luminar -12% rev, Cyngn -40%, Phunware -20%) face revenue declines and cash burns amid narrowing losses in some (Instil Bio -4% loss improvement, Werewolf -14%). Portfolio trends show average revenue growth +100% YoY in crypto-exposed names but -15% in traditional tech/biotech; cash positions deteriorated in 12/20 operating cos (avg -40% YoY), flagging liquidity risks. No insider trading patterns or M&A noted; steady dividends rare (United Guardian $0.60/share). Implications: Favor crypto growth plays for rebound potential, avoid bleeding tech, monitor trusts for any compliance cracks.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 27, 2026

A cluster of 7 small-cap US-listed companies disclosed Nasdaq or NYSE deficiency notices dated March 24-27, 2026, primarily for bid prices below $1.00 over 30 consecutive business days (6/7 cases), with additional issues like late 10-Q filings (Immersion) and deficient stockholders' equity (BiomX). No immediate trading suspensions or delistings, but uniform 180-day cure periods extend to September 2026, with potential second extensions if other standards met. Sentiment is negative across 6/7 filings (Immersion mixed due to dividend declaration), highlighting acute microcap distress without evident period-over-period financial improvements in summaries. Common forward-looking strategies include monitoring bid prices and pursuing reverse stock splits (explicitly noted in 5/7), signaling management efforts to avert OTC migration. Portfolio-level pattern reveals Nasdaq-heavy (5/7) vulnerability in consumer goods, tech services, biotech, and haptics sectors, with no insider buying or bullish capital allocation trends beyond one dividend. Implications include heightened short-term volatility, delisting overhang suppressing multiples, and alpha potential in reverse split bounces or shorts on non-compliance.

7 high priority 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 27, 2026

Across 47 filings in the USA Corporate Distress & Bankruptcy stream, a mix of distress signals and resilience emerges, with 9 companies (HAIN, Alight, ZW Data, SOPA, IMMERSION, BiomX, GIFTIFY, AMERICAN REBEL, BIOMX) facing Nasdaq/NYSE listing deficiencies primarily from sub-$1 bid prices over 30 days, alongside Iterum Therapeutics' bankruptcy petition, but offset by 20+ positive financings, refinancings, and M&A (e.g., TWO Harbors merger at $10.80/share, i-80 Gold $150M prepay). Period-over-period trends are sparse but highlight distress in Origin Materials (Q4 rev -67% YoY to $3M, FY rev -40% to $18.9M, op ex +1100% YoY Q4 due to $178.8M impairment) and covenant relaxations (OFS Capital tangible net assets covenant cut 25% to $75M). Portfolio-level patterns show small-cap biotechs/techs vulnerable to delistings (8/47), while energy/finance firms (Delek, Enterprise Products, Puget Energy) secure larger facilities ($450M-$1.5B), signaling sector rotation opportunities. Forward-looking catalysts cluster in April 2026 (Anaptys spin-off 4/20, Cartesian redemption pre-domestication, Nasdaq cures by Sep). Capital allocation leans defensive (dividends continued pre-merger at TWO, Immersion $0.075/share), with insider alignment via lockups (Streamex co-founders 1-yr voluntary). Overall, distress concentrated in microcaps, but refinancings indicate manageable liquidity for larger names, urging watch on compliance deadlines.

47 high priority 47 total filings
· daily

US Executive Officer Management Changes SEC — March 27, 2026

Across 50 filings in the USA Executive & Director Changes stream (events March 23-27, 2026), a surge in C-level transitions (10+ CEO/CFO changes) and director resignations/not-for-re-election announcements (20+ instances) signals portfolio-wide leadership churn, predominantly neutral with no disagreements cited in 95% of cases. Positive hires in growth-oriented firms like Rumble (AI-savvy CFO), Sturm Ruger (finance transformation expert CFO), MaxCyte (20+ yrs finance CFO), and NCLH (new CEO with $48M equity package tied to TSR CAGR >5-20%) highlight conviction in scaling amid sector tailwinds; negative outlier in Nuwellis (director resignations citing info access disputes). No broad period-over-period financial deterioration evident, but 2026 incentive plans reveal forward thresholds like JAKKS EBITDA >$35.6M (tiered up to $65.6M max bonus), Fuel Tech OI >$250K pool funding, First Industrial FFO/NOI targets (55/30% weighting), implying stable-to-modest growth expectations absent YoY declines. Activist-driven board refreshes (e.g., NCLH/Elliott adding 5 independents) and planned retirements (e.g., SBA EVP Dec 2026) dominate, with mixed comp signals like Traeger discretionary bonuses despite 2025 misses. Implications: Monitor interim leadership risks in biotechs/fintech; bullish for cruise/tech with strong hires; sector churn neutral but flags governance watch in small-caps.

50 high priority 50 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 27, 2026

The USA Bankruptcy & Insolvency intelligence stream highlights a single critical filing from Iterum Therapeutics plc, signaling imminent corporate dissolution amid acute financial distress. Key drivers include severely limited cash resources, ongoing Nasdaq listing non-compliance, failed acquisition discussions for sulopenem, and modest ORLYNVAH sales insufficient to cover high operating costs, with no period-over-period data indicating any positive revenue growth or margin expansion. The Irish High Court petition for winding up, filed March 27, 2026, led to the appointment of Joint Provisional Liquidators Damien Murran and Jennifer McMahon, who may withdraw ORLYNVAH from the U.S. market and oversee subsidiary wind-downs. This development carries maximum materiality (10/10) and uniformly negative sentiment, implying near-total equity value destruction, potential delisting, and disrupted commercialization efforts. Portfolio-level implications point to elevated insolvency risks in small-cap biotech, where cash burn outpaces revenue generation, warranting immediate short positioning or avoidance.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 27, 2026

Across 50 SEC filings on USA Board Room Changes dated March 27, 2026, the dominant theme is elevated executive and board turnover, with 22 resignations/terminations/non-re-elections (44%), 18 appointments/promotions (36%), and 10 compensation/plan updates (20%), signaling transitional instability particularly in biotech/pharma (12/50 filings) and small-caps. Sentiment skews neutral (80%), with positive tones on strategic hires (e.g., Rumble CFO from Intel, Sturm Ruger CFO transition) and mixed/negative on sudden exits (e.g., Cue Biopharma CEO, Nuwellis director disputes). No explicit YoY/QoQ financial deteriorations noted, but interim leadership in 8 cases (e.g., One World, Reed's, Genesco) flags potential execution risks amid bonus plans tied to EBITDA/FFO targets in 5 firms. Activist-driven changes at NCL (board expansion to 9, 4 resign/5 appoint) highlight governance shakeups. Portfolio implications: Monitor small-cap biotechs for volatility; positive hires suggest growth conviction in tech/industrials. Overall, 14 high-materiality events (7-9/10) warrant near-term scrutiny for stock catalysts around AGMs.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — March 27, 2026

The 18 filings reveal a dominant SPAC ecosystem frenzy with 15/18 documents from blank check companies, highlighting IPO completions (BHAV $102M total proceeds, Blue Water IV $134.25M, TRG partial over-allotment to $206.32M total), trust extensions (Ribbon $125K 1-month, Rising Dragon $50K note, IB to Sep 2026, International Media 16th extension to May 2026, Columbus $50K to Apr 2026), and leadership churn (resignations/appointments at AltEnergy, Charlton Aria, Goldenstone). Actual M&A progress includes ETHZilla's $150M 5-year revolving loan purchase commitment (initial $1.44M acquired), Contango ORE's completed 50/50 merger with Dolly Varden yielding >$100M cash/minimal debt, Pelican Holdco's pending merger with loss-making March GL (going concern doubts, $1.67M assets), and Drugs Made's sponsor transition for AI/cyber target with $500K funding commitment. No broad period-over-period trends due to non-operating status of most SPACs, but aggregate fresh trust deposits exceed $500M from IPOs/extensions, signaling robust dry powder for de-SPAC deals into Q2 2026. Neutral-to-positive sentiment prevails (12/18 positive/neutral), with mixed cases tied to distress; portfolio implication is heightened M&A liquidity but execution risks from extensions/churn.

18 high priority 18 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 27, 2026

Overnight SEC filings from March 26-27, 2026, feature 50 documents dominated by proxy statements (DEFA14A/DEF 14A) for May 2026 AGMs across airlines, oil, pharma, and biotech, signaling routine governance but with embedded FY2025 highlights showing mixed performance. Period-over-period trends reveal revenue growth in 8/15 10-Ks (e.g., Sportradar +17% YoY, BitGo +424% YoY, Apollo investment income +1,540% YoY) offset by declines in 7/15 (Luminar -12% YoY, Phunware -19.9% YoY, SpringBig -7.4% YoY), with margin expansions in Indivior (+500 bps to 35%) and Sportradar (+480 bps profit margin) but compressions elsewhere. Biotech shines with clinical wins (Kodiak Phase 3 success, Nurix 83% ORR), while credit funds maintain stable leverage (0.57x-0.82x) and distributions; SPACs/BLANKS show IPO completions and amendments amid no revenues but trust growth. Capital allocation leans shareholder-friendly (Indivior $400M buyback, Oaktree $0.16/share distro, News Corp $1B repurchase), but management churn (resignations at One World, AltEnergy) raises flags. Portfolio-level: Energy/oil mixed (Murphy +3% prod YoY), tech/autonomy challenged (Luminar assets -64% YoY), potential M&A (Brown-Forman/Pernod) as top catalyst. Actionable: Favor biotech/credit longs pre-AGMs, monitor SPAC redemptions.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 26, 2026

Denali Therapeutics' FDA approval of NME orphan drug TIVIDENOFUSP ALFA-EKNM marks the sole bullish signal in a period dominated by 3 neutral generic ANDA approvals (75% of records). This divergence highlights innovative biotech upside for Denali amid routine generic expansions by Aurobindo, Macleods, and Rising. Prioritize Denali for premium pricing potential; generics offer limited alpha due to pricing pressures.

4 total filings
· daily

NME Blockbuster Approvals — March 26, 2026

Denali Therapeutics secured FDA approval for TIVIDENOFUSP ALFA-EKNM (AVLAYAH), a priority-reviewed NME orphan drug (BLA 761485, approved 2026-03-24), delivering a bullish catalyst for near-term revenue via commercial launch and exclusivity benefits. This sole blockbuster in the NME stream underscores regulatory favoritism for orphan designations but highlights data gaps in indication and competition. Institutional investors should prioritize Denali for growth exposure while monitoring label details to quantify market potential.

1 total filings
· daily

New Drug Approvals (Original) — March 26, 2026

One priority-reviewed NME BLA approval for Denali Therapeutics signals bullish biotech momentum with orphan exclusivity potential, dominating the period's 4 approvals. Three standard ANDA generics for Aurobindo Pharma, Macleods Pharms, and Rising add neutral volume but face pricing pressures without designations. Focus institutional capital on Denali for near-term launch upside while viewing generics as low-margin filler.

4 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 26, 2026

HHS BARDA awarded $288M in two large biotech/health R&D contracts in late 2023, providing 4-6 year revenue visibility amid sustained pandemic preparedness funding. Bullish signal for corporate PPD Development LP ($126M, $23M outlayed, to 2029) contrasts neutral nonprofit ATI ($161M, minimal $240k outlay, to 2027), limiting broad equity upside. Monitor outlay acceleration and COVID priorities for execution risks in early-stage, long-duration awards.

2 total filings
· daily

New Federal Contractors — March 26, 2026

HHS dominates with $792.8M in health R&D obligations (45% of total), signaling multi-year federal priority in tobacco studies, biotech, and COVID vaccine tech through 2029. Bullish signals on three corporate/SDVOSB contractors (Westat, AATD, PPD) offer $1.2B+ potential via options/outlays, contrasting neutral nonprofits (Acacia, Advanced Tech). VA IT award to SDVOSB AATD highlights small biz set-aside leverage amid $1.76B total obligations.

5 total filings
· daily

Significant Contract Modifications ($10M+) — March 26, 2026

HHS dominates with $793M (45%) in health R&D contracts through 2029, signaling sustained federal priority on tobacco/health studies, biotech, and COVID immunogenicity amid $1.76B total modifications. Bullish signals for for-profit contractors Westat, AATD, and PPD highlight revenue visibility from high outlays ($122M-$213M disbursed) and options upside ($423M-$960M potential). Neutral nonprofits (Acacia, Advanced Tech) limit equity plays but underscore stable funding in refugee legal and BARDA biotech.

5 total filings
· daily

Contract Deobligations Alert — March 26, 2026

Deobligations alert reveals $1.76B in federal contracts with 3 bullish signals dominating (60% of records, $770M obligations) in HHS health R&D and VA IT services, signaling sustained funding flows. Neutral nonprofit awards ($993M) limit direct equity upside but underscore stable program spending in refugee legal aid and biotech. Investors should prioritize corporates/SDVOSBs with unexercised options (~$607M potential) amid long-term visibility to 2029.

5 total filings
· daily

Contract Option Exercises — March 26, 2026

Five contract option exercises totaling $1.76B highlight bullish signals for for-profit health R&D and VA IT providers (Westat, AATD LLC, PPD), with $770M obligated and strong outlays signaling revenue visibility through 2029. Neutral signals dominate two large nonprofit awards (Acacia, Advanced Technology International) totaling $993M, limiting direct equity upside. Investors should prioritize for-profit entities with unexercised options (~$707M potential) amid HHS/BARDA concentration (45% of value) in long-term R&D.

5 total filings